Indivior PLC





Market Closed - London S.E. 11:35:26 2024-07-12 EDT 5-day change 1st Jan Change
814.5 GBX -3.38% Intraday chart for Indivior PLC -29.78% -31.27%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Oaktree Capital raises stake in UK's Indivior, becomes 2nd largest shareholder RE
UK Stocks-Factors to watch on July 12 RE
Oaktree Capital Management Discloses 6.3% Stake In Indivior As At July 9, Filing Shows RE
Barclays raises Kerry, cuts Hunting, Wood Group AN
London stocks fall as financials and energy stocks drag RE
European companies cut jobs as economy sputters RE
Sector Update: Health Care Stocks Flat to Higher Premarket Tuesday MT
Wall Street Set to Open Marginally Higher as Investors Look Ahead to Powell's Congressional Testimony MT
Sector Update: Health Care MT
Top Premarket Decliners MT
Investors Await Powell's Congressional Testimony as US Futures Trend Slightly Higher MT
Transcript : Indivior PLC - Special Call
Indivior Lowers Fiscal 2024 Net Revenue Guidance, to Discontinue Antipsychotic Injection Perseris -- Shares Tumble Premarket MT
Indivior lowers 2024 outlook and calls time on Perseris AN
Europe's STOXX 600 dips ahead of Powell testimony; Indivior sinks RE
Indivior to Cut 130 Jobs Amid Discontinued Sales of Schizophrenia Drug Perseris MT
London stocks subdued as broader gains offset fall in BP; Powell's testimony in focus RE
UK Pharmaceutical Group Indivior Cuts FY24 Net Revenue Outlook MT
European shares fall ahead of Powell testimony; Indivior drops RE
Indivior shares dive on profit warning, dropping of schizophrenia drug (July 9) RE
UK's Indivior to cut jobs, lowers profit forecast RE
Indivior PLC Announces Discontinuation of PERSERIS Sales & Marketing CI
Indivior PLC Revises Financial Guidance for the Fiscal Year 2024 CI
Indivior PLC Provides Revenue Guidance for the Second Quarter of 2024 CI
Indivior Completes Primary Listing Shift to Nasdaq from London Bourse MT
Chart Indivior PLC
More charts
Indivior PLC is a pharmaceutical company. The Company develops medicines to treat addiction and serious mental illnesses. The Company focuses on building a portfolio of opioid dependence treatments. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder. Its product pipeline focuses on development and discovery of non-opioid treatment strategies for opioid use disorder (OUD), as well as therapies to address the needs of people suffering from alcohol, stimulant, and cannabis use disorders. Its Sublocade, Subutex, and Suboxone are used for the treatment of opioid use disorder (OUD). Perseris is used for the treatment of Schizophrenia. The Company's pipeline products include AEF0117, INDV-2000, INDV-1000, RBP-6000, RBP-7000, Buprenorphine Sublingual and Naloxone Film, and Buprenorphine and Naloxone Sublingual Tablet. Its pipeline also includes the Orexin-1 Receptor Antagonist Program.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
10.58 USD
Average target price
28.42 USD
Spread / Average Target
  1. Stock Market
  2. Equities
  3. INDV Stock
  4. News Indivior PLC
  5. Deutsche Bank Kicks Off Indivior Coverage at Buy